1. Home
  2. GEVO vs MYGN Comparison

GEVO vs MYGN Comparison

Compare GEVO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gevo Inc.

GEVO

Gevo Inc.

HOLD

Current Price

$1.53

Market Cap

421.1M

Sector

Industrials

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$4.55

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GEVO
MYGN
Founded
2005
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
421.1M
444.2M
IPO Year
2010
1996

Fundamental Metrics

Financial Performance
Metric
GEVO
MYGN
Price
$1.53
$4.55
Analyst Decision
Buy
Buy
Analyst Count
3
7
Target Price
$6.58
$7.64
AVG Volume (30 Days)
2.9M
1.4M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
58.82
N/A
EPS
N/A
N/A
Revenue
$711,000.00
$771,400,000.00
Revenue This Year
$19.44
$6.86
Revenue Next Year
$5.59
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$1.12
$3.53
52 Week High
$2.97
$8.59

Technical Indicators

Market Signals
Indicator
GEVO
MYGN
Relative Strength Index (RSI) 39.42 54.92
Support Level N/A $4.31
Resistance Level $1.93 $4.92
Average True Range (ATR) 0.09 0.30
MACD -0.01 0.02
Stochastic Oscillator 30.39 67.30

Price Performance

Historical Comparison
GEVO
MYGN

About GEVO Gevo Inc.

Gevo Inc is a growth-oriented company that focuses on hard to decarbonize market sectors such as jet fuel, certain specialty fuels, on-road fuels, chemicals and materials, and certain products for the food chain such as protein and feeds made as co-products from its processes. It produces and sells competitively priced, renewable, drop-in products for these sectors, and generate carbon abatement value through its plant design and business systems. It owns and operates an ethanol plant with an adjacent CCS facility, Class VI carbon-storage well, and others. The group is currently developing the world's first large-scale ATJ facility to be co-located at the North Dakota site.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: